GlobeNewswire

Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...

Share

WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders (CNS), today announced that The Journal of Clinical Psychiatry has published online results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone (MIN-101).  The results also demonstrated that cognitive improvements correlate with previously reported improvements in negative symptoms.

The manuscript, entitled "Cognitive Effects of MIN-101 in Patients with Schizophrenia and Negative Symptoms: Results from a Randomized Controlled Trial," can be found online at https://doi.org/10.4088/JCP.17m11753

Roluperidone is a novel compound with affinities for 5HT2A and sigma2 receptors and no direct binding to dopamine receptors. In this regard, roluperidone differs from drugs currently indicated for schizophrenia, all of which directly interfere with dopamine neurotransmission.

Results presented in this publication suggest a benefit of roluperidone on cognitive performance in schizophrenia patients with stable positive symptoms and moderate to severe negative symptoms.  Researchers hypothesized that because roluperidone lacks the detrimental effects associated with currently available medications that do not benefit cognitive performance in patients with schizophrenia, the potential beneficial effects on cognition induced by 5HT2Aantagonism and sigma2 antagonism would not be disrupted or diminished by other aspects of the compound's mechanism of action.

"Currently available dopamine-blocking antipsychotic drugs have very little impact on cognitive impairment associated with schizophrenia," said Dr. Richard Keefe, Professor of Psychiatry and Behavioral Sciences at Duke University School of Medicine, CEO of NeuroCog Trials, which provided quality assurance of the cognitive data in the study, and an author of the publication.  "The data from this study suggest that roluperidone, which combines 5HT2A  and sigma2antagonism without dopamine blockade, in addition to improving negative symptoms may improve cognitive deficits in schizophrenic patients."

Cognitive impairment is one of the primary drivers of functional disability in schizophrenia and an unmet medical need.  Cognitive impairment in patients with this disease has been consistently associated with various aspects of diminished functioning, including unemployment, limited social interaction and poor quality of life. 

Cognitive abilities in this study were measured by the Brief Assessment of Cognition in Schizophrenia (BACS) scale at baseline and after 4 and 12 weeks of treatment.   In the analysis of the changes from baseline to the study endpoint (Week 12), scores on a motor test and on a test of verbal fluency were statistically significantly better than placebo.  BACS composite scores (score distribution = .05) showed statistically significant improvement in the roluperidone 32 milligram (mg) group compared to the placebo group.  The score for the BACS composite was close to significance (= .06). There were no significant intergroup differences in the changes in the other BACS domains.

Additional analyses illustrate the correlations between the change in the BACS scores and the change in the Positive and Negative Syndrome Scale (PANSS) negative factor score. 

Previously announced results from this trial, published in the American Journal of Psychiatry, showed that roluperidone achieved its primary outcome in the trial, demonstrating statistically significant superiority over placebo in improving negative symptoms in schizophrenia patients as measured by the pentagonal negative symptoms cluster of the PANSS. The improvement in negative symptoms was shown for both doses tested: 32 mg: p = 0.024 effect size = 0.45, and 64 mg: p = 0.004 effect size = 0.57. 

About The Journal of Clinical Psychiatry

The Journal of Clinical Psychiatry is the official journal of the American Society of Clinical Psychopharmacology (https://www.ascpp.org), which was founded in 1992 to advance the science and practice of clinical psychopharmacology. 

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of current clinical trials and results of clinical trials with roluperidone; the timing and scope of future clinical trials and results of clinical trials with roluperidone; the clinical and therapeutic potential of roluperidone; our ability to successfully develop and commercialize roluperidone; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether roluperidone will be successfully marketed if approved; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018.  Copies of reports filed with the SEC are posted on our website at  www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Standard & Poor’s has affirmed Arion Bank’s long term credit rating BBB+ but revised the outlook from stable to negative23.7.2019 20:32:00 CESTPress release

Standard & Poor’s has affirmed Arion Bank’s long term credit rating BBB+ but revised the outlook from stable to negative. The Bank’s short term credit rating remains A-2. Main comments from Standard & Poor’s: The affirmation of the bank’s ratings reflects that Arion Bank maintains a solid market position in Iceland, with relatively advanced digitalized banking platforms while its exceptional capitalization counterbalances it’s geographic and loan book concentrations. Standard & Poor’s see Arion Bank as being well ahead of many other European banks in its preparation for technological disruption In a fiercely competitive environment, no longer supported by a strong economy, Icelandic banks' business prospects and earnings have become weaker. Furthermore, the role of pension funds in lending distorts Icelandic banks' competitive environment in terms of business generation and margins. Therefore it is seen as a negative trend for industry risk. Overall, economic risks for Icelandic banks

All Regulatory Clearances for Saxo Bank and BinckBank obtained to close the Offer23.7.2019 18:20:00 CESTPress release

This is a joint press release by BinckBank N.V. (BinckBank), Star Bidco B.V. (the Offeror) and Saxo Bank A/S (Saxo Bank, pursuant to Section 4, paragraph 3 of the Dutch decree on public takeover bids (Besluit openbare biedingen Wft) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary and priority shares in the capital of BinckBank (the Offer). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the Offer Memorandum dated 12 March 2019 (the Offer Memorandum). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States or Canada or in any other jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum. All Regulatory Cleara

Golar LNG Partners LP Cash Distributions23.7.2019 18:13:00 CESTPress release

Golar LNG Partners LP (“the Partnership”) (NASDAQ: GMLP) announced today that its board of directors has approved a quarterly cash distribution with respect to the quarter ended June 30, 2019 of $0.4042 per common and general partner unit. This cash distribution will be paid on August 14, 2019 to all common and general partner unitholders of record as of the close of business on August 7, 2019. A cash distribution of $0.546875 per Series A preferred unit (NASDAQ: GMLPP) for the period from May 15, 2019 through August 14, 2019 has also been declared. This will be payable on August 15, 2019 to all Series A preferred unitholders of record as at August 8, 2019. Golar LNG Partners LP Hamilton, Bermuda July 23, 2019 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2019 RESULTS23.7.2019 18:00:00 CESTPress release

Almere, The Netherlands July 23, 2019, 6 p.m. CET ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2019 RESULTS ASM International N.V. (Euronext Amsterdam: ASM) today reports its second quarter 2019 operating results (unaudited) in accordance with IFRS. FINANCIAL HIGHLIGHTS EUR million Q2 2018 Q1 2019 Q2 2019 New orders 175.9 235.0 373.1 Net sales 208.7 248.8 363.3 Gross profit margin % 42.1 % 41.3 % 59.0 % Operating result 38.3 47.0 150.2 Result from investments (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013) 21.6 3.1 2.0 Amortization intangible assets (resulting from the sale of ASMPT stake in 2013) (3.0 ) (3.4 ) (3.4 ) Net earnings 59.4 49.4 121.6 Normalized net earnings (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013 and result from sale of ASMPT shares) 62.4 52.8 125.0 • New orders were €373 million. Excluding €103 million related to the patent litigation settlement new orders were €270 million. • Net